Source: Chr. Hansen Holding A/S
Chr. Hansen and Lonza establish a 50/50 joint venture to pioneer the emerging market for live biotherapeutic products
Company Announcement No. 4/2019
Announcement attached below
For further information, please contact:
Head of Investor Relations
Martin Riise
Tel.: +45 5339 2250
Investor Relations Officer
Annika Stern
Tel.: +45 2399 2382
Head of Media Relations
Camilla Lercke
Tel.: +45 5339 2384
Attachment